Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-03-20
2007-03-20
Gambel, Phillip (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388700, C435S069600, C435S326000, C435S332000, C435S334000, C435S343000, C435S343100, C435S346000, C536S023500, C536S023530, C424S130100, C424S133100, C424S141100, C424S143100, C424S144100, C424S153100, C424S173100
Reexamination Certificate
active
10693629
ABSTRACT:
An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.
REFERENCES:
patent: 5677165 (1997-10-01), de Boer et al.
patent: 5786456 (1998-07-01), Ledbetter et al.
patent: 5801227 (1998-09-01), Fanslow, III et al.
patent: 5874082 (1999-02-01), de Boer
patent: 6004552 (1999-12-01), de Boer et al.
patent: 6051228 (2000-04-01), Aruffo et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 2004/0120948 (2004-06-01), Mikayama et al.
patent: 0 945 465 (1999-09-01), None
patent: 0 972 445 (2000-01-01), None
patent: 91/09115 (1991-06-01), None
patent: 96/33735 (1996-10-01), None
patent: 96/34096 (1996-10-01), None
patent: 99/39726 (1999-08-01), None
patent: 99/42075 (1999-08-01), None
patent: 99/55369 (1999-11-01), None
patent: 99/61051 (1999-12-01), None
patent: 00/00156 (2000-01-01), None
patent: 00/75348 (2000-12-01), None
patent: 01/16180 (2001-03-01), None
patent: 01/24823 (2001-04-01), None
patent: 01/56603 (2001-08-01), None
patent: 01/83755 (2001-11-01), None
patent: 0183755 (2001-11-01), None
patent: 02/12501 (2002-02-01), None
patent: 02/28904 (2002-04-01), None
patent: 03/029296 (2003-04-01), None
patent: 03/040170 (2003-05-01), None
patent: 03/040170 (2003-05-01), None
Suzuki t al., Transplantation 82 (1 Suppl 2) p. 609, Jul. 15, 2006; Abstract #1624.
Yamada et al., “Generation of Mature Dendritic Cells from a CD14+Cell Line (XS52) by IL-4, TNF-α, IL-1β, and Agonistic Anti-DC40 Monoclonal Antibody”,J. Immunol., 1999; 163(10): 5331-5337, XP002302209.
van Kooten et al., “Functions of CD40 on B cells, dendritic cells and other cells”,Curr. Opin. Immunol., 1997; 9(3): 330-337, XP004313522.
Stout et al., “The many roles of CD40 in cell-mediated inflammatory responses”,Immunol. Today, 1996; 17(10): 487-492, XP004034711.
An et al.; Ligation of CD40 Potentiates Fas-Mediated Activation of the Cysteine Protease CPP32, Cleavage of Its Death Substrate PARP, and Apoptosis in Ramos-Burkitt Lymphoma B Cells; Cellular immunology, vol. 181; 1997; pp. 139-152.
Baccam et al.; Membrane-bound CD154, but not CD40-specific antibody, mediates NF-xB-independent IL-6 production in B cells; Eur. J. Immunol., vol. 29; 1999; pp. 3855-3866.
Barr et al.; Functional activity of CD40 antibodies correlates tot he position of binding relative to CD154; Immunology, vol. 102; 2001; pp. 39-43.
Boon et al.; Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys; Toxicology, vol. 174; 2002; pp. 53-65.
Challa et al.; Epitode-dependent synergism and antagonism between CD40 antibodies and soluble CD40 ligand for the regulation of CD23 expression and lgE synthesis in human B cells; Allergy, vol. 54; 1999; pp. 576-583.
Clark et al.; Activation of human B cells mediated through two distinct cell surfa ce differentiation antigens, Bp35 and Bp50; Proc. Natl. Acad. Sci. USA, vol. 83; Jun. 1986; pp. 4494-4498.
Clark et al.; CDw40 and BLCa-specific monoclonal antibodies detect two distinct molecules which transmit progression signals to human B lymphocytes; Eur. j. Immunol., vol. 18; 1988; pp. 451-457.
de Boer et al.; Generation of monoclonal antibodies to human lymphocyte cell surface antigens using insect cells expressing recombinant proteins; Journal of Immunological Methods, vol. 152; 1992; pp. 15-23.
Diehl et al.; CD40 activationin vivoovercomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy; Nature Medicine, vol. 5, No. 7; Jul. 1999; pp. 774-779.
Dullforce et al; Enhancement of T cell-independent immune responsesin vivoby CD40 antibodies; Nature Medicine, vol. 4, No. 1; Jan. 1998; pp. 88-91.
Erickson et al.; Short-circuiting long-lived humoral immunity byt the heightened engagement of CD40; The Journal of Clinical Investigation, vol. 109, No. 5; Mar. 2002; pp. 613-620.
Francisco et al.; Construction, Expression, and Characterization of BD1-G28-5 sFv, a Single-chain Anti-CD40 Immunotoxin Containing the Ribosome-inactivating Protein Bryodin 1; The Journal of Biological Chemistry, vol. 272, No. 39; Sep. 1997; pp. 24165-24169.
Francisco et al.; Agonistic Properties and in Vivo Antitumor Activity of the Anti-CD40 Antibody SBN-14; Cancer Research, vol. 60; Jun. 2000; pp. 3225-3231.
Funakoshi et al.; Inhibition of Human B-Cell Lymphoma Growth by CD40 Stimulation; Blood, vol. 83, No. 10, May 1994; pp. 2787-2794.
Funakoshi et al.; Differential In Vitro and In Vivo Antitumor Effects Mediated by Anti-CD40 and Anti-CD20 Monoclonal Antibodies Against Human B-Cell Lymphomas; Journal of Immunotherapy, vol. 19, No. 2; 1996; pp. 93-101.
Hasbold et al.; Properties of mouse CD40: cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies; Eur. J. Immunol., vol. 24; 1994; pp. 1835-1842.
Hasbold et al.; Cell division number regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL-4; Eur. J. Immunol., vol. 28; 1998; pp. 1040-1051.
Heath et al.; Monoclonal antibodies to murine CD40 define two distinct funtional epitopes; Eur. J. Immunol., vol. 24; 1994; pp. 1828-1834.
Hirano et al.; Inhibition of Human Breast Carcinoma Growth by a Soluble Recombinant Human CD40 Ligand; Blood, vol. 93, No. 9; May 1999; pp. 2999-3007.
Karlsson et al.; Selection of human single chian antibodies against CD40; Immunology Letters, vol. 73, Nos. 2, 3; Sep. 2000; p. 161, abstract No. 358.
Kedl et al.; CD40 stimulation accelerates deletion of tumor-specific CD8+T cells in the absence of tumor-antigen vaccination; PNAS, vol. 98, No. 19; Sep. 2001; pp. 10811-10816.
Kwekkeboom et al.; CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells; Immunology, vol. 79; 1993; pp. 439-444.
Kwekkeboom et al.; Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by cd-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction; Eur. J. Immunol., vol. 24; 1994; pp. 508-517.
Lagerkvist et al.; Single, Anitgen-Specific B Cells Used to Generate FAb Fragments Using CD40-Mediated Amplification or Direct PCR Cloning; BioTechniques, vol. 18, No. 5; 1995; pp. 862, 864-869.
Ledbetter et al.; Augmentation of Normal and Malignant B Cell Proliferation by Monoclonal Antibody to the B Cell-Specific Antigen BP50 (CDW40); The Journal of Immunology, vol. 138, No. 3; Feb. 1987; pp. 788-794.
Ledbetter et al.; Agonistic Activity of a CD40-Specific Single-Chain Fv Constructed from the Variable Regions of mAb G28-5; Critical Reviews in Immunoloby, vol. 17; 1997; pp. 427-435.
Malmborg Hager et al.; Affinity and Epitope Profiling of Mouse Anti-CD40 Monoclonal Antibodies; Scandinavian Journal of Immunology, vol. 57; 2003; pp. 517-524.
Maxwell et al.; Contrasting the Roles of Costimulation and the Natural Adjuvant Lipopolysaccharide During the Induction of T Cell Immunity; The Journal of Immunology, vol. 168; 2002; pp. 4372-4381.
Mazzei et al.; Recombinant Soluble Trimeric CD40 Ligand Is Biologically Activve; The Journal of Biological Chemistry, vol. 270, No. 13; Mar. 1995; pp. 7025-7028.
Murphy et al.; Antibodies to CD40 Prevent Epstein-Barr Virus-Mediated Human B-Cell Lymphomagenesis in Severe Combined Immune Deficient Mice Given Human Peripheral Blood Lymphocytes; Blood, vol. 86, No. 5; Sep. 1995; pp. 1946-1953.
Paulie et al.; A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes; Cancer Immunology Immunotherapy, vol. 20; 1985; pp. 23-28.
Pound et al.; Minimal cross-linking and epitope requirements for Cd40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells; International Immunology, vol. 11, No. 1; 1999; pp. 11-20.
Rolink et al.; The SCID but Not theRAG-2 Gene Product Is Required for Sμ-Sε Heavy Chain Class Switching; Immunity, vol. 5; Oct. 1996; pp. 319-330.
Romano et al.; Triggering of CD40 Antigen Inhibits Fludarabine-Induced Apoptosis in B Chronic Lymphocytic Leukemia Cells; Blood, vol. 92, No. 3; Aug. 1998; pp. 990-995.
Schoenberger et al.; T-cell help for cytotoxic T ly
Chen Xingjie
Force Walker R.
Mikayama Toshifumi
Takahashi Nobuaki
Yoshida Hitoshi
Gambel Phillip
Kirin Beer Kabushiki Kaisha
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
Anti-CD40 monoclonal antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-CD40 monoclonal antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-CD40 monoclonal antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3772751